(AsiaGameHub) - The legislative effort against prediction markets pressed forward strongly on Thursday, with lawmakers unveiling yet another bill aimed at the sector.
Sens. Elissa Slotkin (D-MI), Todd Young (R-IN), Adam Schiff (D-CA), and John Curtis (R-UT) are spearheading this bipartisan initiative, known as the Public Integrity in Financial Prediction Markets Act of 2026, which seeks to prohibit government officials from leveraging insider information to gain profits from event contracts.
As drafted, the legislation aims to stop federally elected officials, political appointees, and government employees from utilizing their access to sensitive, nonpublic information—acquired through their trusted roles—to execute trades on prediction markets.
Similar to other proposals, this legislation comes in the wake of multiple reports of alleged insiders securing substantial profits by making suspiciously timely trades ahead of major geopolitical events, including the joint U.S.-Israeli strikes on Iran, where six accounts earned $1.2 million.In a press release announcing the bill, Young referenced these worries:
“Public service should never be a pathway to personal profit based on insider information. Recent activity in prediction markets has raised real concerns that individuals with access to sensitive, nonpublic information could exploit that advantage for financial gain.”
This measure joins a growing number of bills targeting the industry, as lawmakers from both parties voice concerns over insider trading, sports contracts, and markets linked to war and government actions.
Bill Covers Congress, Executive Branch Staff & Political Appointees
The proposed bill aims to address what many view as an ethics gap, as prediction markets are being used more frequently as financial tools, sparking worries about insider trading.
Under the legislation, “covered individuals” would encompass the president, vice president, members of Congress, and employees of executive or independent regulatory agencies. Those in these categories would be prohibited from using:“Material nonpublic information that a reasonable investor would deem significant when making a decision about a prediction market contract and that is not publicly accessible.”
The bill would establish strict penalties and reporting requirements:
Authorizes fines of $500 or double the profit from the trade, whichever is higher.
Oversight ethics offices are required to establish regulations, issue guidance, and collect reports on transactions exceeding $250.
Any covered individual involved in a transaction worth over $250 must submit a detailed report to their oversight ethics office within 30 days.
Slotkin stressed why she believed the bill is needed:
“No one should profit from the information and knowledge gained through public service, plain and simple. This bill is a crucial initial step in establishing commonsense regulations for prediction markets, with real enforcement to ensure those who violate these rules face tangible consequences. I’m proud of our bipartisan group and thank Senators Young, Schiff, and Curtis for collaborating with me to advance this critical legislation.”
Curtis noted that the bill would apply long-standing insider-trading principles to a new form of financial product. Schiff, on the other hand, contended that the industry cannot be left to regulate itself.
Competitive Field of Prediction Market Legislation
The Public Integrity in Financial Prediction Markets Act enters an already packed arena of legislative proposals competing for attention on Capitol Hill, as members of Congress aim to define their stances in the debate. In January, Rep. Ritchie Torres (D-NY) introduced a House version of the same act.
On the same day Slotkin, Young, Schiff, and Curtis introduced this bill, Sen. Jeff Merkley (D-OR) and Rep. Jamie Raskin (D-MD) unveiled the STOP Corrupt Bets Act, a bicameral bill that would prohibit prediction market betting on elections, government actions, and military operations.
Other recent proposals include the End Prediction Market Corruption Act by Merkley and Sen. Amy Klobuchar (D-MN), Schiff’s DEATH BETS Act, and the Prediction Markets Security and Integrity Act of 2026 by Sens. Richard Blumenthal (D-CT) and Andy Kim (D-NJ).
Other bills advancing through Congress include the Prediction Markets Are Gambling Act by Sens. John Curtis (R-UT) and Adam Schiff (D-CA), and the PREDICT Act by Reps. Adrian Smith (R-NE) and Nikki Budzinski (D-IL), which focuses on political event contracts.
Considering the number of bills under consideration in Congress, one thing is clear: Congress is seeking to address what it perceives as the prediction market issue from various perspectives. Though no single bill has yet distinguished itself, it appears lawmakers have no plans to ease the pressure on prediction markets in the near future.
This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content.
AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
(AsiaGameHub) - The British government is working to alleviate the financial strain on charities addressing gambling harm as they navigate a new, and at times contentious, funding system.
According to the Department for Culture, Media and Sport (DCMS), which oversees gambling regulation in the UK, the statutory research, education, and treatment (RET) levy has generated nearly £120 million in its inaugural year.
This substantial amount is earmarked specifically for research into, prevention of, and treatment for gambling-related harm. However, the transition from the previous funding arrangements to the new model has posed difficulties for some charitable organizations.
To address these challenges, the DCMS has established a three-month transition grant fund. This grant will be accessible to UK charities focused on gambling harm from April 1 to June 1, 2026. In instances where the DCMS makes a decision after April 1, charities will be permitted to submit claims retroactively.
Charities will be required to meet specific eligibility criteria to be considered for a grant.
Eligible organizations must have been engaged in 'relevant activity' in March 2026 to support service users in England. Furthermore, they must have previously applied for and been unsuccessful in securing funding from the gambling levy through either the Gambling Harms Prevention VCSE Grant Fund or the Gambling Harms Treatment VCSE Grant Fund.
The purpose of this grant is to cover staffing costs and associated overheads necessary for the continued operation of charity services. Capital expenditures, defined as any spending that results in the creation or improvement of an asset valued at over £2,000, are not eligible for funding.
Organizations have until April 30, 2026, to submit their grant applications.
Charities navigate a controversial shift
The levy was a key component of the Gambling Act review, replacing the former system where operators voluntarily contributed 1% of their revenue to GambleAware. GambleAware then managed the commissioning of RET projects nationwide.
Invoices for the statutory levy were first issued by the UK Gambling Commission (UKGC) on September 1, 2025, with a payment deadline of October 1, 2025. The levy is now an annual obligation for licensed operators, with invoices dispatched on September 1 each year.
However, the introduction of the levy has not been without controversy, and several charities have expressed concerns regarding the long-term viability of the UK's gambling harm research, education, and treatment system under the new funding structure.
NHS England, which is undergoing restructuring, has assumed responsibility for treatment funding. The Office for Health Improvement and Disparities (OHID) will oversee prevention efforts, and UK Research and Innovation (UKRI) will manage research initiatives.
GambleAware ceased operations earlier this month, as its commissioning functions have been effectively transferred to the NHS. The charity had long advocated for the establishment of a statutory levy, but with itself retaining the lead role in commissioning.
Various charitable organizations voiced alarm at these changes when the Gambling Act review White Paper was published in April 2023, and have continued to do so.
For instance, the Gambling Lived Experience Network (GLEN) shared some frustrations on LinkedIn just last week. However, the organization did offer some commendation for OHID, describing its performance as significantly better than that of NHS England and UKRI.
Is there any going back?
Regardless of the opinions held by charities, it appears that the statutory levy is a permanent fixture. Even if the government were to reconsider its position, such a significant undertaking would require considerable time to reverse.
The process of commissioning services is also well underway. In Scotland, the devolved government has begun allocating its £7.9 million share of the UK-wide gambling levy. These funds will be distributed among the NHS, local authority partners, and the third sector, which includes charities.
Scotland's Public Health Minister, Jenni Minto, stated: “Gambling harm is a significant issue affecting far too many people in Scotland. It impacts not only individuals who gamble but also their families, relationships, communities, and society as a whole.
“We are already working diligently with partners to mitigate this, and these awards represent a major step forward. This funding will support a variety of projects and programs for individuals dealing with what is often an unseen issue.
“Data indicates that over two percent of Scottish adults – more than 90,000 individuals – may be problem gamblers. The funding provides a balanced approach across the third sector, including community and voluntary organizations, and services delivered through the NHS and local authorities.”
The largest beneficiaries include the RCA Trust (£1 million), Public Health Scotland (£967,000), NHS Greater Glasgow and Clyde (£926,000), Fast Forward (£561,000), Citizens Advice Scotland (£450,000), and Simon Community Scotland (£445,000).
Other recipients are Gambling With Lives (£124,000), Charity Space Scotland (£47,000), Scottish Ambulance Service (£45,000), Young Scot (£30,000), and Dundee and Angus College (£52,000).
The RCA Trust, the largest recipient, offers counseling services for individuals affected by gambling-related harm and other conditions such as drug and alcohol abuse. Andy Todd, a spokesperson for the charity, commented:
“The funding provided by the Scottish Government will be crucial for the ongoing delivery of prevention, education, training, treatment, and support for those impacted by gambling harms across Scotland.
“With gambling harms now being addressed through a public health model, we look forward to collaborating with partners to reduce harms by expanding service provision, decreasing stigma, and working with lived experience perspectives to integrate policy and practice among frontline staff.”
The distribution of gambling harm treatment funding in Scotland follows the Welsh government's announcement of how its share of the RET levy funds would be allocated nine months prior. However, there is still no confirmation regarding how funds will be utilized in England.
Overall, the government anticipates raising between £90 million and £100 million annually from the levy. According to the DCMS, this target was exceeded in its first year, yet there remains no clarity on how these funds will be spent in England, the UK's largest nation.
This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content.
AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
(AsiaGameHub) - Live casino products provide limitless opportunities for operators in the U.S., as stated by Mor Weizer, Chief Executive Officer of Playtech, during an interview with SBC News.
Shortly after Playtech released its full-year 2025 results, Weizer told us that the Group will stay focused on expanding the live casino market in the U.S., even though the product has lower adoption rates than in many other global regions.
“We see the U.S. as a huge opportunity,” he noted. “Live casinos are indeed very popular in Asia, and they’re also well-received in some other markets—there are countries where live casino makes up 25-30% of total gaming activity.
“In the U.S., as you rightly noted, adoption rates are still limited to around 17%. However, we see this as a chance because we are confident that the U.S. market’s fundamentals will enable significant growth in live casino.
“As we stated earlier today, live casino customers generate 1.8 times more revenue than regular casino players, which creates a cross-selling opportunity for operators to expand live casino offerings in the U.S. further.”
A Global Shield Against Tax Burdens
The Americas region overall has been a critical contributor to Playtech’s financial performance over the past year, particularly as the company undergoes a rapid transition to a B2B-focused business. However, a notable point from the FY25 report was that B2B costs rose while B2B revenue declined year-over-year (YoY).
When asked if Playtech can reverse this trend in 2026, Chris McGinnis, Chief Financial Officer, noted that revenue was affected by the updated agreement with Caliente International, but costs are projected to increase at a slower pace this year, and profits are expected to return to growth alongside this.
Looking ahead, this year is set to bring higher tax burdens in several of Playtech’s key markets, including Brazil and the UK. Nevertheless, the company’s management is confident that Playtech can weather these challenges due to its diversified portfolio.
McGinnis explained: “The most significant impact for Playtech has been in the UK, where the government announced an increase in the Remote Gaming Duty. We issued a statement indicating that this would have a major effect on our business.
“But we remain optimistic. Playtech is geographically diversified, so even with tax hikes in the UK and other regions, we are still confident that we will continue to grow.”
Weizer further emphasized: “We have a strong presence in other markets such as Italy, Spain, France, Poland, Romania, and the Scandinavian region. This broad diversification means we are well-equipped to handle any regulatory changes that may arise.”
Finally, Playtech confirmed that it is exploring several new markets to boost its diversification, specifically Finland, New Zealand, and Ireland.
All three nations are currently implementing major regulatory changes.
Finland is working to end its state-run gambling monopoly with operator Veikkaus by June 2027, New Zealand is set to launch its first online gambling licenses, and Ireland has a new gambling regulator that will reshape the country’s domestic market.
Weizer concluded: “Finland is adopting a new regulatory framework that will allow operators to enter the market openly. We view this as a chance to deepen our partnership with Veikkaus.
“We also have existing Scandinavian partners who are eager to enter the Finnish market as soon as the regulatory changes take effect.
“New Zealand, meanwhile, is currently unregulated but is considering introducing regulations. Playtech is seeking to partner with operators that are likely to establish themselves there, including both B2B partners and structured agreement partners.
“As for Ireland, they are also revising their regulatory framework. We see this as an opportunity due to our strong connections with individuals who have access to the Irish market.”
This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content.
AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
HONG KONG, March 23, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited ("CORXEL"). Under the agreement, the Company has acquired the rights to develop, manufacture, and commercialize CARDAMYST™ (etripamil) nasal spray in Greater China, including Chinese Mainland, Hong Kong, Macao and Taiwan region.Under the terms of the agreement, Everest will pay CORXEL an upfront payment of US$30 million (equivalent to approximately RMB344,895,000), as well as potential development milestone payments of up to US$20 million (equivalent to approximately RMB137,958,000). As part of this agreement, Everest will be assigned and transferred rights, interests, claims, duties, obligations and liabilities (other than certain excluded liabilities) under the Milestone License Agreement entered into by CORXEL in May 2021 and certain related ancillary agreements.CARDAMYST™ (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker as administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. In December 2025, CARDAMYST was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. As a rapid-acting treatment option, CARDAMYST can be self-administered outside the emergency department or other healthcare settings, enabling patients to actively manage episodes and gain greater control over their condition. In addition to its approved indication for PSVT, etripamil nasal spray is also under clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR). Phase II trials have shown encouraging results, and Phase III trials are planned, with the potential to further extend its therapeutic impact to a broader patient population.In China, the New Drug Application (NDA) for etripamil nasal spray was accepted by the National Medical Products Administration (NMPA) on January 17, 2025 and is expected to receive approval in the third quarter of 2026.PSVT is characterized by abnormalities in the heart's electrical system that cause sudden unexpected and often severely symptomatic episodes of rapid heart rate. There are currently no approved self-administered, fast-acting, non-injectable therapies for acute PSVT, leaving patients with limited treatment options beyond emergency care. Approximately 2.3 to 4 per 1,000 individuals are affected by PSVT, representing an estimated 3 to 6 million patients in China.AFib-RVR is a type of irregular heart rhythm, characterized by an irregular and elevated heart rate. Its onset is typically gradual, episodes are less likely to terminate spontaneously, and the condition tends to recur, significantly increasing the risk of thromboembolism and serious complications such as stroke and heart failure. In China, atrial fibrillation affects an estimated 1.6% of the population, representing nearly 20 million patients, and is expected to increase with an aging population. Both PSVT and AFib-RVR are associated with a loss of control and a significant psychological burden for patients.Overall, the combined patient population for PSVT and AFib-RVR exceeds 25 million, representing a significantly unmet clinical need that urgently requires more convenient and more effective treatment options.In terms of clinical data, the NDA for etripamil nasal spray was accepted by the NMPA based on data from the pivotal global Phase 3 RAPID study and the China Phase 3 JX02002 study. Both trials met their primary endpoints. Overall, the treatment emergent adverse events (TEAEs) were comparable between the etripamil and placebo groups. The FDA approval of CARDAMYST was supported by a robust clinical program that included safety data from more than 1,800 participants across more than 2,000 PSVT episodes. This included the Phase 3 RAPID trial, a global, randomized, double-blind comparison of etripamil versus placebo, published in The Lancet in 2023. The RAPID trial achieved its primary endpoint, with 64% of participants who self-administered etripamil (N=99) converting from supraventricular tachycardia (SVT) to sinus rhythm within 30 minutes compared with 31% on placebo (N=85) (HR = 2.62; p<0.001). The median time to conversion was 17 minutes (95% CI: 13.4, 26.5) for etripamil versus 54 minutes (95% CI: 38.7, 87.3) for placebo. Etripamil nasal spray is also under clinical development for AFib-RVR. In the randomized, controlled Phase-2 ReVeRA study, etripamil demonstrated rapid and significant reduction in ventricular rate in patients with AFib-RVR, achieving its primary endpoint. A greater number of patients receiving etripamil achieved a ventricular rate of less than 100 bpm (58.3%) than those receiving placebo (4%). The safety profile was consistent with previous studies.From a strategic perspective, this transaction is also seen as an important step for the Company in implementing 2030 Strategy. Driven by its 2030 Strategy, and led by Mr. Yifang Wu, Chairman of the Board, Everest is accelerating growth through a dual-engine approach that combines strategic business development partnerships with in-house R&D. This transaction further strengthens Everest's expanding cardiovascular franchise, building on recent strategic initiatives and reinforcing the Company's disciplined approach to constructing focused therapeutic verticals with meaningful lifecycle expansion potential. Through continued advancement of its pipeline and product portfolio globally, Everest aims to deliver innovative therapies to more patients, create sustainable long-term value, and advance its position to become a leading global biopharmaceutical company."We are pleased to collaborate with CORXEL, this agreement marks an important step in our continued expansion in the cardiovascular field and a meaningful milestone in advancing our growth 2030 strategy," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "CARDAMYST is currently the only therapy designed for at-home self-administration to enable the acute termination of PSVT and AFib-RVR episodes, addressing a significant unmet medical need among patients in China. We will leverage our clinical development expertise and established commercialization platform to accelerate its advancement and future launch in Greater China, while further strengthening our cardiovascular franchise and unlocking its broader potential across atrial arrhythmias."As the registration and commercialization of Etripamil nasal spray progress, the company aims to further expand its cardiovascular portfolio. Leveraging its established clinical development and commercialization capabilities, Everest Medicines will accelerate the delivery of innovative assets, advance its 2030 strategy, and bring more treatment options to patients. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
(AsiaGameHub) - Despite ongoing discussions about marketing budget reductions, sports sponsorship activity within the global betting and gaming sector shows no signs of deceleration.
The past fortnight has seen a new surge of agreements spanning motorsport, football, baseball and sports data.
This Sponsor Spotlight examines the worldwide platform of Formula 1, explores various football agreements throughout Europe, and ventures across the Atlantic to identify which iGaming operators are establishing a presence in the US market and their specific locations.
Allwyn races to the forefront of Formula 1
Following a successful inaugural season, Formula 1 has prolonged its collaboration with Allwyn via a new multi-year contract.
The agreement capitalises on Formula 1's sustained international expansion, with the sport now reaching 827 million supporters and a total television viewership of 1.8 billion. The refreshed partnership prioritises enhancing fan interaction through digital and interactive initiatives.
A significant enhancement involves Allwyn's incorporation into the F1 Predict platform, enabling fans to predict race results through the newly created "Allwyn League", with rewards including grand prix tickets and Paddock Club entry. The brand will also achieve greater exposure during formation laps, representing one of the most prominent segments of a race weekend.
This development follows a momentous period for the UK's National Lottery operator, encompassing the release of its financial results, finalisation of its OPAP merger, and exceeding the £450 million investment threshold for National Lottery modernisation.
Tipico scores in the nation of its headquarters
Tipico Group has entered into a multi-year contract with the Malta Football Association, securing status as an official partner of the national squad.
Departing from conventional sponsorship models, this arrangement focuses on employer brand development, specifically promoting Tipico's recruitment platform and drawing local expertise in technology, finance and business positions.
The collaboration encompasses branding on team kits, stadium promotions and digital media, all designed to boost recognition among Malta's labour pool and reinforce Tipico's standing as a permanent employer in what has become a favoured location for iGaming companies.
PureWager goes in to bat for Baltimore Orioles
PureWager Group has entered the US professional sports arena via a sponsorship agreement with the Baltimore Orioles.
This designation establishes PureWager as the sole sports betting partner of the baseball organisation and involves establishing the PureWager Pavilion at Oriole Park, Camden Yards, conceived as a communal area for supporters.
The deal coincides with PureWager's preparations to debut its wagering and online casino platform in the United States, with intentions to expand into numerous states after an initial launch in Michigan.
Eurobet.live taps into ‘second screen’ trend with AS Roma
Eurobet.live has secured a multi-year sponsorship with AS Roma, assuming the role of the club's principal shirt sponsor until the 2028/29 campaign.
The collaboration is notable for its emphasis on infotainment over conventional sportsbook marketing, seeking to comply with Italy's stringent advertising restrictions.
Eurobet.live will assume a pivotal function in AS Roma's digital content approach, generating matchday material, interviews and social media elements. The agreement targets the "second screen" demographic – supporters who interact with statistics and content whilst viewing matches.
Veikkaus sponsor capitalises on a Scandinavian niche
Finnish National Lottery operator Veikkaus Oy has been appointed principal partner of this year's men's Floorball World Championships, hosted in Finland.
Finland's men's team enters the competition as defending world champions, having secured the title in Sweden during 2024.
The sport has surged in popularity throughout Scandinavia, with final weekend tickets already exhausted, as Veikkaus seeks to leverage this momentum through sponsorship and broaden brand recognition before significant industry reforms in Finland.
Spotlight rankings: Who’s standing out?
1: Formula 1 / Allwyn
Viewed globally, this partnership is particularly prominent. Combining Formula 1's extensive reach with Allwyn's expanding sporting footprint, it unites two substantial organisations on a worldwide platform. Both entities have also experienced recent international expansion.
2: PureWager / Baltimore Orioles
Entering the US sports market via an MLB franchise provides PureWager with a robust foundation for establishing brand recognition before a broader rollout.
3: Eurobet.live / AS Roma
Italy's wagering market ranks as Europe's second-largest, and the revised regulatory structure has been well received. Gaining exposure through a prominent Serie A club represents a shrewd strategic decision.
4: Tipico / MFA
While Malta stands among the globe's most significant gambling centres, its domestic market remains relatively modest by European standards due to the country's limited population. Nevertheless, preserving positive relationships with local sporting partners is always advisable.
5: Veikkaus Oy / Floorball
Finally, Veikkaus' most recent sponsorship initiative does not match the scope of other agreements examined here. Nonetheless, it aligns perfectly with the company's reputation as a socially conscious operator, potentially offering significant advantages when Finland liberalises its market to additional licensees in 2027.
This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content.
AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - As AI accelerates into the inference era, enterprise-grade AI is achieving large-scale deployment, driving an exponential surge in Token consumption and ushering data demand into a new development stage. Against this backdrop, high-quality, structured and scenario-specific professional data has become critical for enterprises to forge core strategic competitiveness in the era of AI.As a leading provider of AI real-time data infrastructure and analysis services in China, Xunce Technology is rapidly solidifying its core position in AI data, driven by industry tailwinds, full-chain technological capabilities and diversified growth engines. Amid the unfolding landscape of the intelligent economy, this ten-year industry stalwart is entering a pivotal window for structural revaluation.Token Value Restructuring: Making Every Data Access Quantifiable and MonetizableFounded in 2016, Xunce Technology has built a full-chain technological system spanning data acquisition, cleansing, standardization, real-time computing and large- model optimization over a decade of development. With AI Data Agent at its core, the Company specializes in millisecond-level real-time data processing, serving a diversified portfolio of industries including finance, urban governance, high-end manufacturing, healthcare, robotics, satellite applications, low-altitude economy, electric power, power grids and energy.As the era of AI inference unfolds, Token is evolving from mere “fuel” to a form of “hard currency”. Maximizing the value of each individual Token has emerged as a central challenge in the large-model inference era. Today, general-purpose large models typically rely on a “computing power for precision” approach, where every inference run generates substantial wasteful Token consumption. Should inference fail, all Tokens expended in the process are lost entirely, which is a common pain-point plaguing general AI systems.By contrast, vertical AI solutions equip general large language models with an external industry “brain” powered by domain-specific data. At its core, such solutions optimize inference logic via business-aware models, enabling upfront task feasibility validation and eliminating Token waste at the source. With deep expertise in professional vertical domain data modeling, Xunce Technology leverages its extensive portfolio of high-quality, scenario-specific proprietary data to act as an “efficiency multiplier” for every Token invocation. This structure translates Token consumption into higher-precision outputs while securing maximal result certainty. Crucially, the Company is developing full-chain capabilities spanning data metering, pricing and settlement, enabling quantifiable and monetizable measurement for every data access. By elevating per-unit Token efficiency, it delivers enhanced business value to enterprise clients.Aligned with this strategy, Xunce’s platform features a “LEGO-inspired” modular architecture, enabling clients to flexibly compose modules tailored to their specific needs. This “assemble-on-demand, adapt-in-real-time” design fosters deep and long-term customer stickiness. The Company also employs a highly flexible pricing framework, with fees structured around module count, processing throughput and other key metrics. Supported by subscription, transaction-based and Token-based payment models, its pricing mechanism precisely aligns with diverse client demands.Currently, Xunce Technology is fully building a full-chain data measurement and settlement system. It is exploring pricing mechanisms tied to large model inference frequency and module usage count, allowing customers to pay for effective Tokens rather than raw computing power consumption.Inflection Point Reached, Profitability ConfirmedDriven by Token value restructuring and innovative business models, Xunce Technology has delivered robust performance and reached a historic inflection point. In H2 2025, the Company posted an adjusted net profit of RMB 50 million, achieving its first positive profitability. Meanwhile, revenue rose from RMB 197.85 million in H1 2025 to RMB 1,086.81 million in H2, representing a 449.32% quarter-on-quarter surge. Amid rapid business expansion, the Company has witnessed a substantial improvement in profitability.Explosive Revenue GrowthReturn to Profit in H2Doubled ARPU & Per Capita GrowthImproved Cash Flow & Operating Metrics+103% Y/YNarrowed by 33%+105% Y/YSignificant Improvement2025 full-year revenue YoY growth2025 full-year adjusted net loss2025 ARPU YoY growth2025 net operating cash flow+449% H/HRMB 50 million+135% Y/YAmple cash on hand in 20252025 H2 revenue HoH growth2025 H2 adjusted net profit2025 per capita revenue YoY growthAverage collection period decreased in 2025For the full year, the Company posted total operating revenue of RMB 1,284.66 million, representing a substantial year-on-year increase of 103.28% and successfully breaking the key milestone of RMB 1 billion in revenue. This signifies that the Company has evolved from an early-stage, technology-driven startup into a new era of platform-based development with scalable and replicable business models.Furthermore, the Company’s combined gross proceeds for 2025 amounted to approximately RMB 792.08 million, representing a substantial increase of 63.44% compared to approximately RMB 484.63 million in the previous year. In terms of adjusted net loss, after deducting one-off non-recurring gains and losses, the Company’s adjusted net loss for 2025 was RMB 54.84 million, representing a significant narrowing of 33% from RMB 82.37 million in 2024.Notably, the Company achieved combined gross margin of 62% in 2025, exceeding that of Cambricon (55%), a leading AI chip provider, and far outpacing general large- model developer Minimax (25.4%). This underscores its high-value strategic positioning and resilient business model in the AI data infrastructure sector.In terms of R&D investment, Xunce Technology has also maintained efficient growth conversion. In 2025, the Company’s R&D expenditure reached RMB 450.44 million, with R&D expenses accounting for 48% of revenue, driving a 105% year-on-year increase in operating revenue. For comparison, Minimax’s R&D expenditure accounted for as high as 219% of its revenue, with a revenue growth rate of 159%. Xunce achieved a comparable expansion pace with a lower R&D intensity.As revenue scale continues to expand and gross margin in new industries gradually stabilize, the Company’s short-term objective is to achieve an inflection point in adjusted net profit. Looking ahead, as the industries already deployed enter a period of margin stabilization and Token-based payment and revenue-sharing models gain accelerated traction, its net profit is poised to improve at an accelerated rate.Driven by Diversified Growth Engines, Business Structure Continuously OptimizedThe robust revenue growth is not accidental, but underpinned by Xunce Technology’s multi-dimensional, systematically structured growth framework.Accelerate cross-industry replication. The Company currently covers 9 major industries, benchmarking Palantir’s 17 industries and leaving ample room for horizontal expansion. Xunce Technology is rapidly deepening its presence in key national strategic sectors such as asset management, telecommunications, electric power, urban management, high-end manufacturing, healthcare, energy, robotics training platforms and commercial aerospace. For each new industry, the Company first completes industry-specific data accumulation over 3 to 5 years, enabling rapid replication and scaled deployment across peer customers thereafter.The business model fosters deep customer value enhancement. As customers evolve from single-module adoption to multi-module deployment, and from pilot trials to full integration into core business workflows, substantial upside potential in ARPU remains. By synergistically lifting Token invocation volume, module usage count and per-Token value, the Company will unlock a new dimension of growth.Steadily expand overseas business and establish a global layout. The Company targets raising its overseas revenue share to 10% to 15% in 2026, and will further escalate its globalization strategy during 2027 and 2028, unlocking new avenues for sustained long-term growth.Cultivate a strategic cooperative ecosystem to forge deep integration with upstream and downstream partners in computing power and algorithms. Xunce Technology is engaging in in-depth collaboration with leading domestic GPU providers and large language model enterprises to build a one-stop solution encompassing “infrastructure computing power, upper-layer applications and data governance,” further solidifying its core position in the AI data infrastructure sector. Pioneer cutting-edge applications to seize commanding heights in future industries. From robotics data platforms to commercial aerospace, low-altitude economy and power grid systems, Xunce Technology has taken the lead in extending AI infrastructure to emerging sectors with stringent demands for real-time performance and operational reliability. Such mission-critical scenarios with ultra-high requirements for data timeliness and stability serve as a rigorous validation of the Company’s technological advantages. The Company will continue to ramp up R&D investment in frontier fields, refine its technical capabilities through high-end application scenarios and unlock new high-growth, high-value growth tracks for long-term development.Evolving from Data Services to Core AI Economy Infrastructure: Building Sustainable Competitive BarriersFrom a macro perspective, the artificial intelligence data sector is witnessing a profound convergence of five defining trends: a surge in demand for real-time, secure, high-quality data in the era of AI Agent; the rise of domain-specific models elevating professional data as a critical enabler for industry-wide intelligent upgrading; standardization of data interfaces driven by next-generation AI operating systems including Open Claw, positioning Xunce Technology as a core data Token provider; Token-based payment emerging as a new paradigm for the data element market; and the implementation of data asset capitalization policies, spurring a sharp rise in enterprises’ mandatory investment in data governance.At the intersection of these five pivotal trends, Xunce Technology has established a robust fundamental logic for sustained long-term growth. The Company has evolved beyond a traditional data infrastructure provider to become a critical “connector” and “enabler” linking large models, computing power and cloud vendors. By integrating upstream models, downstream computing power and horizontal collaboration with cloud vendors, the Company delivers irreplaceable data-centric value to its enterprise clients.The Company stresses that it shares a natural upstream-downstream synergy with general large-model providers, rather than a competitive dynamic. Analogous to the deep collaboration between GPU manufacturers and model developers, the value of Xunce Technology lies in a mutually reinforcing cycle: the wider the adoption of models by its clients, the greater the opportunity for the Company to deliver services and generate incremental value for clients.Notably, in contrast to niche market players offering only isolated modules such as data cleansing or computing engines, Xunce Technology’s core differentiation lies in its full-process coverage and outcome-driven accountability. The Company provides an end-to-end solution spanning data acquisition, cleansing, standardization, modeling, real-time computing and model tuning, ensuring that final data delivered to clients is clean, accurate, real-time and accessible for model invocation at millisecond latency. Furthermore, through deep integration into clients’ private clouds or on-premises environments, the Company acts as a dedicated data steward, fostering exceptional customer stickiness and forging robust, sustainable competitive barriers.Currently, the Company’s product portfolio and solutions feature more than 300 functional modules, covering a full spectrum of scenarios from data infrastructure to upper-layer analytics applications. In 2025, its active paid clients base reached 230, with an outstanding customer retention rate of 90%. ARPU increased substantially from RMB 2.72 million in 2024 to RMB 5.59 million in 2025, representing a year-on-year growth of over 103%.As algorithms become increasingly open-source and computing power tends toward standardization, what truly sets companies apart lies in data — particularly industry data that has undergone sophisticated governance and can effectively empower large models. Backed by a decade of deep industry expertise, Xunce Technology has established a substantial and sustainable competitive barrier in this domain.ConclusionFrom an early-stage private equity tool provider to a cross-industry AI data infrastructure builder, and from a module supplier to a Token-priced core platform, Xunce Technology has remained committed to unlocking data as a scarce, strategic resource that is freely circulable, readily callable and empowered to drive high-quality decision-making.Amid the rapid emergence of new intelligent economic paradigms, the Company stands at the threshold of a fundamental structural revaluation, with the potential to enter the RMB 100-billion market cap camp. It is a competitor to none, but an indispensable partner to all. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and MSD K.K. (Headquarters: Tokyo, Representative Director: Prashant Nikam, “MSD”), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan for the additional dosage and administration in combination with WELIREG® (belzutifan), the first-in-class oral hypoxiainducible factor-2 alpha (HIF-2α) inhibitor from MSD, for the treatment of unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.This application is based on the results of the Phase 3 LITESPARK-011 trial evaluating the dual regimen of LENVIMA plus WELIREG for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy. The data from this trial were presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in February 2026. At a pre-specified interim analysis with a median follow-up of 29.0 months (range, 19.3-49.2), the LENVIMA plus WELIREG combination therapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), one of the primary endpoints, reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. The safety profile of this combination was consistent with those reported for each agent administered as monotherapy, and no new safety signals were identified.In 2022, approximately 435,000 people worldwide were newly diagnosed with kidney cancer, and about 156,000 people died from the disease. 1 In Japan, it is estimated that roughly 21,000 people were newly diagnosed and about 7,000 died in 2022.2 RCC accounts for approximately 85% of kidney cancers3, and the five-year survival rates for patients with stage III and IV RCC have been reported as 63%–78% and 27%–28%4, respectively, indicating that the disease still has a high unmet medical needs.LENVIMA is approved in combination with KEYTRUDA ® (pembrolizumab) in Japan for the first-line treatment of unresectable or metastatic RCC. WELIREG is approved in Japan for the treatment of unresectable or metastatic RCC that has progressed following cancer chemotherapy. Additionally, supplemental New Drug Applications (sNDA) for the LENVIMA and WELIREG combination therapy for the treatment of adult patients with advanced RCC with a clear cell component following a PD-1 or PDL1 inhibitor has been accepted by the U.S. Food and Drug Administration (FDA), with a PDUFA (Prescription Drug User Fee Act) target action date set for October 4, 2026.Eisai and MSD have been collaborating through the provision of information on LENVIMA in Japan since October 2018, and will work together to expedite the maximization of contribution to patients with cancer.About LENVIMA (lenvatinib)LENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1- 4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below.Thyroid cancer- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable thyroid cancerThe United States: The treatment of patients with locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer (DTC)Europe: The treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)Hepatocellular carcinoma- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable hepatocellular carcinomaThe United States: The first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)Europe: The treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy- Indication in combination with KEYTRUDA (generic name: pembrolizumab) and transarterial chemoembolization (Approved in China)Thymic carcinoma- Indication as monotherapy (Approved in Japan)Japan: Unresectable thymic carcinomaRenal cell carcinoma (In Europe other than the United Kingdom, the agent was launched under the brand name Kisplyx®)- Indication in combination with everolimus(Approved mainly in the United States, Europe and Asia) The United States: The treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapyEurope: The treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Radically unresectable or metastatic renal cell carcinomaThe United States: The first-line treatment of adult patients with advanced renal cell carcinomaEurope: The first-line treatment of adult patients with advanced renal cell carcinomaEndometrial carcinoma- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapyThe United States: The treatment of patients with advanced endometrial carcinoma that is pMMR or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiationEurope: The treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery.About WELIREG (belzutifan)WELIREG, Merck & Co., Inc., Rahway, NJ, USA’s, known as MSD outside of the United States and Canada, first-in-class hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, is an orally administered small-molecule designed to reduce transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth. By inhibiting HIF-2α signaling, WELIREG aims to disrupt key pathways certain tumors may use to adapt to low-oxygen conditions, including those that help promote abnormal blood vessel formation and support tumor survival. WELIREG has demonstrated antitumor activity in certain von Hippel-Lindau (VHL) diseaseassociated tumors, renal cell carcinoma and in pheochromocytoma or paraganglioma. As part of a broader clinical program, Merck & Co., Inc., Rahway, NJ, USA continues to research WELIREG monotherapy and combination approaches for people with genitourinary, breast and gynecologic cancers across a range of treatment settings to further define where HIF-2α inhibition may provide clinical benefit and to better understand which patients are most likely to respond. WELIREG has been approved in Japan for the treatment of certain von Hippel–Lindau (VHL) disease–associated tumors, as well as for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.LITESPARK-011 ResultsData from LITESPARK-011 (ClinicalTrials.gov, NCT04586231) were presented at the ASCO GU Symposium held in February 2026. LITESPARK-011 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT04586231) evaluating WELIREG in combination with LENVIMA compared to cabozantinib for the treatment of patients with advanced clear cell RCC that has progressed on or after anti-PD-1/L1 therapy. The dual primary endpoints are progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by blinded independent central review (BICR), and overall survival (OS). Secondary endpoints include objective response rate (ORR) per RECIST v1.1 as assessed by BICR, duration of response (DOR) per RECIST v1.1 as assessed by BICR, and safety. The trial enrolled 747 patients who were randomized to receive WELIREG (120 mg orally once daily) plus LENVIMA (20 mg orally once daily) or cabozantinib (60 mg orally once daily).At a pre-specified second interim analysis with a median follow-up of 29.0 months (range, 19.3- 49.2), WELIREG plus LENVIMA demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS, reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. For WELIREG plus LENVIMA, the median PFS was 14.8 months (95% CI, 11.2-16.6) versus 10.7 months (95% CI, 9.2-11.1) for cabozantinib. A trend toward improvement in overall survival (OS), the trial’s other primary endpoint, was also observed for WELIREG plus LENVIMA (HR=0.85 [95% CI, 0.68-1.05]; p=0.06075). The median OS was 34.9 months (95% CI, 27.5-NR) for WELIREG plus LENVIMA versus 27.6 months (95% CI, 24.0-31.4) for cabozantinib. The trial is continuing, and OS will be evaluated at a subsequent analysis per the clinical trial protocol. Regarding secondary endpoints, at the first interim analysis with a median follow-up of 19.6 months (range, 9.9-39.8), WELIREG plus LENVIMA met ORR, demonstrating a statistically significant improvement compared to cabozantinib. A confirmed ORR of 52.6% (95% CI, 47.3-57.7) was observed for WELIREG plus LENVIMA versus 39.6% (95% CI, 34.6-44.8) for cabozantinib. At the second interim analysis with a median follow-up of 29.0 months, the median DOR was 23.0 months (95% CI, 2.0-44.3+) for WELIREG plus LENVIMA versus 12.3 months (95% CI, 1.8+-35.9+) for cabozantinib. WELIREG plus LENVIMA was administered to 370 patients and cabozantinib was administered to 371 patients. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 71.6% of patients receiving WELIREG plus LENVIMA versus 65.8% of patients receiving cabozantinib. Adverse events led to treatment discontinuation in 11.1% of patients receiving WELIREG plus LENVIMA and in 11.3% of patients receiving cabozantinib, respectively. Serious adverse events were observed in 51.6% of patients receiving WELIREG plus LENVIMA versus 43.9% of patients receiving cabozantinib, and AEs led to death in 5.4% of patients (two were treatment-related: thrombotic microangiopathy [n=1] and pneumonitis [n=1]) versus 3.2% (one was treatment-related: hemoptysis [n=1]) of patients, respectively.About the Eisai and Merck & Co., Inc., Rahway, NJ, USA Strategic CollaborationIn March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA, and HIF-2α inhibitor, WELIREG.Eisai’s focus on cancerEisai acknowledges “Oncology” as one of its key strategic areas, and will continue to focus on the discovery and development of anti-cancer drugs within drug discovery domains including “microenvironment”, “protein integrity and homeostasis”, and “cell lineage and cell differentiation” under the Deep Human Biology Learning (DHBL) drug discovery and development organization. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains, with the aim of contributing to the cure of cancers.6. About EisaiEisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept [also known as our human health care (hhc) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners. For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia, and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (U.S. and global), LinkedIn (for U.S. and EMEA) and Facebook (global).Merck & Co., Inc., Rahway, NJ, USA’s Focus on CancerEvery day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncologyAbout MSDAt MSD (the name by which Merck & Co., Inc., Rahway, NJ, USA, is known outside of the United States and Canada), we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.co.jp and connect with us on Facebook, Twitter, and YouTube.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf, accessed 27 Mar 2026.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/392-japan-fact-sheet.pdf, accessed 27 Mar 2026.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. 2025; 2026 Version 1. Rose TL and Kim WY. Renal cell carcinoma: a review. JAMA. 2024 Sep 24;332(12):1001– 10.Media InquiriesEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120MSD K.K.Communications DivisionTatsuro MuraseTEL: +81 (0)70-8700-0112 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
香港, 2026年3月27日 - (亚太商讯 via SeaPRwire.com) - 随着人工智能加速迈向推理阶段，企业级AI迎来规模化落地，Token消耗呈指数级攀升，数据需求进入全新发展阶段。在这一趋势下，高质量、结构化、场景化的专业数据，正成为AI时代企业构建核心战略竞争能力的关键所在。作为中国领先的AI实时数据基础设施及分析服务商，迅策科技得益于赛道红利，凭借全链路技术能力与多元增长引擎驱动，正加速确立其在AI数据层的核心地位。随着智能经济新形态的全面展开，这家深耕十年的企业正迎来结构性价值重估的窗口期。Token价值重构：让每一次数据调用都可量化、可计价迅策科技成立于2016年，历经十年发展，已构建起覆盖数据获取、清洗、标准化、实时计算至大模型调优的全链路技术体系。公司以AI Data Agent为核心，专注于毫秒级实时数据处理，服务领域涵盖金融、城市运营、高端制造、医疗、机器人、卫星、低空经济、电力、电网及能源等多元化产业。在AI推理时代开启的当下，Token正从"燃料"进化为"硬通货"。如何将每一个Token的价值最大化，成为大模型推理阶段的核心命题。当前，通用大模型普遍采用"用算力换精度"的策略，每一次推理都伴随着大量无效Token消耗。一旦推理失败，前期投入的Token全部作废——这是通用AI面临的共同困境。相比之下，垂类AI解决方案则是用行业数据为通用大模型安装一个"外脑"。其核心在于用业务模型优化推理路径，提前判断任务可行性，从源头避免Token浪费。长期深耕专业垂类数据建模领域的迅策科技，凭借其多年积累的高质量、场景化垂类数据，相当于为每一次Token调用加装了"增效器"，在消耗 Token 时换取更高精度的结果，实现最高的产出确定性。更为关键的是，公司正在构建全链路的数据计量、计费、结算能力，使每一次数据调用，都可量化、可计价，通过提升每单位Token的有效性，为客户带来更高的业务价值。围绕这一思路，迅策科技的平台采用"乐高式"模块化架构，让客户可以根据自身需求灵活组合模块，实现"按需装配、随需而变"，建立深度黏性。公司在定价与收费模式上亦遵循灵活设定，基于模块数量、处理速度等维度，销售采用订阅制、交易制以及按Token收费制的模式，以精准匹配客户需求。目前，迅策科技正全力构建全链路的数据计量与结算体系，探索按大模型调用次数与模块应用个数等维度计价，让客户为"有效Token"付费，而不是为算力消耗买单。业绩拐点已现，盈利能力得到验证在Token价值重构背景与商业模式创新的推动下，迅策科技业绩表现强劲，迎来历史性拐点：2025年下半年，公司实现经调整净利润0.5亿元，首次实现半年度正向盈利。此外，公司在2025年上半年实现营收1.98百万元，下半年营收跃升至10.87百万元，环比激增449%。公司在高速扩张的同时，盈利能力已开始实质性释放。全年来看，公司实现营业收入达1,284.66亿元，较上年同期大幅增长103.28%，成功跨越"十亿营收"这一关键门槛，标志着公司已从早期技术驱动的初创阶段，正式迈入可规模化复制的平台化发展新纪元。此外，2025年公司综合毛利约为人民币792.08百万元，较上年度约人民币484.63百万元大幅增加63.44%。经调整净亏损方面，扣除一次性非经常性损益后，公司2025年度经调整净亏损为人民币54.84百万元，较2024年度的82.37百万元大幅收窄33%。值得注意的是，2025年公司综合毛利率达62%，不仅高于以AI芯片为核心业务的寒武纪（55%），更远超通用大模型公司Minimax（25.4%），体现出其在AI数据基础设施领域独特的高价值卡位与商业模式韧性。在研发投入方面，迅策科技亦保持了高效的增长转化。2025年公司研发开支达450.44百万元，研发支出占收入比重为48%，驱动营业收入实现105%的同比增长；相比之下，Minimax研发支出占比高达219%，收入增幅为159%。迅策以更低的研发强度，实现了接近同等级别的扩张速度。随着收入规模持续扩大、新行业毛利逐步收敛，公司短期盈利目标为实现经调整净利润迎来拐点。未来随着已投入行业陆续进入毛利收敛期，以及Token付费与分成模式加速落地，公司净利率有望加速提升。多元增长引擎驱动，业务结构持续优化业绩的强劲增长并非偶然，背后是迅策科技多维驱动、系统推进的增长逻辑。加速跨行业复制。公司目前覆盖9大行业，对标Palantir的17个行业，横向拓展空间广阔。迅策科技正加速向资管、电信、电力、城市管理、高端制造、医疗、能源、机器人训练平台、商业航天等国家重点发展的行业纵深拓展。每进入一个新行业，公司先用3-5年完成行业数据沉淀，随后便可实现同行业客户的快速复制推广。商业模式驱动客户价值深耕。 随着客户从单一模块走向多模块部署、从局部试用走向核心业务流程嵌入，ARPU值仍有显著提升空间。通过Token调用次数、模块应用数量及单次Token价值的协同提升，公司将打开全新的增长空间。稳步开拓海外业务，构建全球化布局。公司规划2026年海外收入占比提升至10-15%，2027-2028年持续提升全球化战略，为长期增长开辟新的空间。构建战略合作生态，与算力及算法上下游深度绑定。迅策科技正与国内头部GPU厂商及大模型公司深度合作，构建"底层算力+上层应用+数据治理"的一站式解决方案，进一步巩固其在AI数据层的核心地位。开拓前沿应用，抢占未来产业制高点。从机器人数据平台到商业航天、低空经济、电力电网，迅策科技率先将AI基础设施延伸至对实时性、可靠性要求极高的新兴领域，这些对数据实时性、可靠性要求极致的场景，正是公司技术优势的最佳试金石。公司将持续加大在前沿领域的研发投入，以尖端场景锤炼技术能力，为未来发展开辟高增长、高价值的新赛道。从数据服务商到AI经济核心基础设施，构建深厚竞争壁垒宏观层面来看，人工智能数据领域正迎来五大趋势的深度交汇：AI Agent时代对实时、安全、高质量数据的需求爆发；垂类模型崛起使专业数据成为行业智能化升级的关键要素；Open Claw等新一代AI操作系统将数据接口标准化，迅策科技正成为核心数据Token供应商；Token化付费成为数据要素市场的新范式；数据资产入表政策落地，企业对数据治理的刚性投入需求激增。在这五大趋势的交汇点上，迅策科技逐步构筑起长期发展的坚实底层逻辑。迅策科技不再只是数据基础设施提供商，而是连接模型、算力、云厂商的"连接器"与"赋能者"。向上连接模型，向下连接算力，横向协同云厂商，最终为客户提供不可替代的数据价值。公司强调，其与通用大模型公司是天然的上下游合作关系，而非竞争关系。正如GPU厂商与模型公司深度合作一样，迅策科技的价值在于：客户使用的模型越多，公司的服务机会越多，为客户创造的价值也越多。值得关注的是，与市场上仅做数据清洗、或仅做计算引擎的单一模块厂商不同，迅策科技的核心差异在于全流程覆盖与为结果负责的能力。从数据获取、清洗、标准化、建模、实时计算，到模型调优，提供端到端解决方案，确保最终输出给客户的数据是干净的、准确的、实时的、可被模型秒级调用的。同时，公司深度嵌入客户的私有云或本地系统，扮演"数据管家"角色，形成极高的客户粘性与竞争壁垒。目前，公司产品与解决方案拥有超过300多个功能模块，覆盖从数据基础设施到上层分析的全场景。2025年，公司的付费客户活跃量达到230家，客户留存率高达90%。ARPU值从2024年的272万元，再大幅提升2025年559万元，同比增幅超过103%。当算法走向开源，算力趋于标准化，真正拉开差距的，是数据——尤其是经过深度治理、能够驱动大模型的行业数据。迅策科技凭借十年深耕，已在这一领域构建起深厚的护城河。结语从早期私募工具到跨行业的AI数据基建，从"模块供应商"到"Token计价平台"，迅策科技始终致力于让数据成为真正可流动、被调用、可驱动决策的稀缺资源。在智能经济新形态加速到来的今天，这家公司正站在结构性重估的起点上, 或进入千亿市值阵营。它不是任何人的竞争者，而是所有人都需要的合作伙伴。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and MUFG Bank, Ltd. (“MUFG Bank”), a consolidated subsidiary of Mitsubishi UFJ Financial Group, Inc. (TYO: 8306, “MUFG”) today announced a new Memorandum of Understanding (MoU) to expand NextGen, their business co-creation model. Building on their collaboration launched in May 2024*1 and further developed as announced in May 2025*2 , NextGen combines Hitachi’s technology and operational expertise with MUFG’s financial capabilities to accelerate the transition to decarbonized mobility.*1 MUFG’s Business Co-Creation and Investment into UK Battery as a Service project by Hitachi ZeroCarbon May 2024*2 Hitachi ZeroCarbon and MUFG unite technology expertise with financial support to accelerate fleet electrification May 2025NextGen was initially validated through a UK pilot project with First Bus, where the parties collaborated via a special purpose vehicle (SPV) to support the procurement and operation of electrification assets under a Battery-as-a-Service model. This expanded MoU extends NextGen beyond battery-focused structures, enabling broader and more scalable deployment across additional markets outside the UK and across a wider range of asset classes. These include emobility assets such as electric vehicles and charging infrastructure, associated energy management systems, and potentially extending to energy hubs supporting industrial assets, power grids and data centers.Hitachi and MUFG Bank will also develop and scale SPV structures to finance decarbonized mobility assets for fleet and transport operators. This approach removes capital constraints and accelerates implementation, enabling operators to focus on their core transport services. From Hitachi’s side, the initiative is led by its Strategic SIB Business Unit, bringing together expertise from across Hitachi including Hitachi Energy, as ‘One Hitachi’. Hitachi will also provide managed services for asset performance and lifecycle optimization, supported by data-driven solutions from Hitachi ZeroCarbon. Through this initiative, Hitachi aims to further advance and streamline mobility and charging infrastructure operations by expanding HMAX by Hitachi, a suite of next-generation solutions that embodies Lumada 3.0, differentiated by deep domain knowledge and AI.Electrifying commercial transport at pace will require an unprecedented deployment of vehicles, charging and energy infrastructure - alongside innovative financing models to support it. Global investment in electrified transport reached around US$750 billion in 2024, making it the largest segment of the energy transition worldwide*3 - yet many fleet operators face limited access to capital and the operational complexity of transitioning at scale. Against this backdrop, Hitachi and MUFG Bank aim to expand NextGen as a repeatable model to accelerate implementation by combining structured asset financing with managed services and data-driven optimization.*3 Sources: BloombergNEF’s Energy transition Investment Trends 2025In demonstration of the expanded pipeline, Hitachi ZeroCarbon and MUFG Bank have also entered into an MoU with Boreal Norge AS and its subsidiary Boreal Buss AS, one of Norway’s primary transport operators, providing transport services across several counties and employing around 3,000 employees across its fleet, which includes over 850 buses and 35 ferries. The parties will explore how they can support Boreal’s transition planning, de-risk operations, optimize services and strengthen competitiveness as concessions evolve.Jun Taniguchi, Senior Vice President and Executive Officer, CEO of Strategic SIB Business Unit, at Hitachi, Ltd. said:“We are delighted to advance this partnership which combines Hitachi’s deep expertise in social infrastructure and digital technologies with MUFG Bank, Ltd.’s financial strength to accelerate the transition to a decarbonized society. By improving the performance of assets such as batteries and charging infrastructure through Hitachi’s digital services led by HMAX, we can truly help customers optimize the total cost of ownership. This partnership embodies our One Hitachi approach, leveraging our diverse capabilities across the Group to support our customers in achieving their net-zero ambitions.”Masakazu Osawa, Senior Managing Executive Officer Chief Executive, Japanese Corporate & Investment Banking Business Unit of MUFG Bank, Ltd., said:“Building on MUFG’s Business Co‑Creation and Investment approach, this collaboration with Hitachi aims to create value through strategic partnerships that improve society and the environment. For the global EV market, our focus is not only on strengthening Hitachi’s leading position in Battery as a Service, but also on fostering a holistic value chain — including second‑ life battery markets — that supports the acceleration of electric mobility and the achievement of 2050 net‑zero targets. Together with our partners, we are committed to co‑creating sustainable businesses that become a driving force for progress worldwide.”Nikolai Knudsmoen Utheim, Group CEO, Boreal Norge AS said:“Our priority has always been to deliver first-class transport services to our customers, whether that’s on the road, rail or over water. In exploring how we can unlock the power of electrified fleets, we can not only deliver more sustainable operations, but upgrade our infrastructure and thread technology across our entire business model for more efficient, smart transport and energy management.”About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com.About MUFGMitsubishi UFJ Financial Group, Inc. (MUFG) is one of the world’s leading financial groups. Headquartered in Tokyo and with over 360 years of history, MUFG has a global network with approximately 2,000 locations in more than 40 countries. The Group has about 150,000 employees and offers services including commercial banking, trust banking, securities, credit cards, consumer finance, asset management, and leasing. The Group aims to “be the world’s most trusted financial group” through close collaboration among our operating companies and flexibly respond to all of the financial needs of our customers, serving society, and fostering shared and sustainable growth for a better world. MUFG’s shares trade on the Tokyo, Nagoya, and New York stock exchanges. For more information, visit https://www.mufg.jp/english.About BorealBoreal is a leading mobility provider, operating buses, fast ferries, passenger ferries and trams in Norway and Sweden. We remain firmly committed to our societal mission of encouraging more people to travel collectively. At the same time, we are more than public transport. As the only company operating buses, ferries, fast ferries, trams and tourism services, we deliver integrated mobility solutions and travel experiences. Although Boreal is a young company in name, its heritage extends back more than 150 years. The company has around 3,000 employees and is headquartered in Stavanger, Norway. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results for the year ended 31 December 2025 (“the Year” or “FY2025”) with net profit growth, contracts-in-hand achieving another record high and order intake more than doubled, providing a solid business foundation for the coming three years and beyond.Financial Highlights- Profit attributable to owners of the Company increased 23.5% to HK$167.0 million.- Contracts-in-hand surged 61.8% to HK$17,878.7 million, hitting another record-high, made possible by a 113.7% increase in order intake to HK$12,913.6 million during the Year.- The intake of new maintenance contracts for housing programmes, environmental projects and lifts and escalators increased 51.4% to HK$1,669 million, reinforcing the recurring revenue stream.- The Group maintained a strong cash position, with bank balances and cash of HK$1,020.8 million and gearing ratio reduced to 10.1% for FY2025 from 26.2%.- The Board has resolved to pay a second interim dividend of HK2.9 cents per share. Total dividend for the year amounted to HK5.5 cents per share with 25.6% increment year-on-year.Chairman Dr Mak Kin Wah said, “The Year 2025 saw profound changes around the world, with challenges and yet also opportunities. Our Group has continued to stride forward: upholding what we commit by delivering the fundamentals well, striving for continuous improvement to make transformation actionable, investing in technology advancement and productivity, and bringing Hong Kong’s engineering excellence to the world. We are pleased to report that the Group achieved profit growth, secured a record level of contracts-in-hand, and continued to build on our international market presence. These accomplishments highlight our distinctive comprehensive capability across diverse business segments, our commitment to excellence, and our leadership in advanced engineering techniques.”“Supported by strong cashflow, we are in a strong position to take on additional work where appropriate and to seize high-value opportunities as they arise. We will continue to stay agile and focused on capturing opportunities across our broad portfolio, build on our competitive strengths through continuous improvement, and reinforce the use of innovative solutions that enhance quality, safety and performance. We remain steadfast in our commitment to our customers, recognising that this is fundamental to earning their trust and cultivating enduring, strategic partnerships. Guided by our motto – ‘We Commit. We Perform. We Deliver’ – we will continue to maximise value for customers, shareholders, suppliers and stakeholders, while contributing to the communities we serve.”Business Review: Building Services- This segment remains the largest revenue contributor, with revenue reaching HK$3,279 million.- Contracts-in-hand reached a record-high level of HK$8,297 million with the total value of new contracts secured in FY2025 doubled to HK$6,470 million. The Group’s competitive edge in multidisciplinary packaged projects and its industry leadership in innovative MiMEP and other new engineering techniques helped it to secure major contracts.- With strategic investments to accelerate innovation and modern manufacturing facilities in Zhuhai and Hong Kong, the Group continues to lead in MiMEP and DfMA technologies.- Following the successful acquisition of a property management licence, the Group expanded its business to deliver integrated solutions across the entire building lifecycle. This new capability, spanning construction, maintenance, operations and long-term facility management, creates a potential revenue stream that complements core services.- Through continuous development of innovative technologies and operational optimisation, the segment is positioning itself to maintain the market competitiveness while exploring opportunities in other markets in Southeast Asia.Environmental Engineering- This segment achieved record-high contracts-in-hand and order intake, increasing 86.9% and 253.7% to HK$8,094 million and HK$5,355 million respectively. Segment revenue also increased by 18.0% year-on-year to HK$1,591 million.- The segment maintained active tendering throughout the period and was awarded significant contracts, including contracts of a record-breaking value to relocate sewage treatment works in Sha Tin to caverns, sewage pumping station at Ma On Shan and more.- Formed a joint venture company in Qingyang city to explore the operation and maintenance business in the Chinese Mainland.- Explored project opportunities in Asia and the Middle East and the expansion of its expert services into Europe.Information, Communications and Building Technologies (“ICBT”)- Segment revenue remained at HK$630 million. Contracts-in-hand totalled HK$852 million at the year end, and order intake was HK$523 million during the Year.- This segment continued to reinforce its leadership in green and intelligent building solutions under the DigiFusion brand, to enable the development of smarter, more sustainable urban environments.- Continued to leverage ATAL Tower as a platform for developing innovative technologies and broaden its technological capabilities through strategic collaborations with leading manufacturers in the Chinese Mainland and around the world, to strengthen its ability to deliver scalable, high-performance solutions across a wide range of sectors.Lifts and Escalators- Revenue and order intake increased 11.0% to HK$587 million and by 3.2% to HK$566 million respectively.- Transel Elevator & Electric Inc. (TEI), the associate company in the United States (US), secured a contract for the world-class vertical transportation system in the iconic 56-storey luxury hotel skyscraper on the border of Times Square in New York. TEI also further strengthened its market position by extending its footprint into the Southeastern part of US.- Actively built on its presence in the UK and broadened its network across other international markets, reinforcing its global ambitions in vertical transportation solutions.- Machine-Room-Less lift products continued to gain traction in key international markets- Streamlined the manufacturing processes of Nanjing factory, broadened its product portfolio and strengthened the overall product quality, aligning with the Group’s global vision and reaffirming its commitment to delivering reliable, high-performance vertical transportation solutions.For further details of the 2025 Annual Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.About Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in the Chinese Mainland, Macau, the United States, the United Kingdom, Germany, Singapore and Malaysia. Serving a wide spectrum of customers from public and private sectors, the Group provides multidisciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.The Group also manufactures and sells lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd. (603912.SS), specialises in manufacturing of precision air conditioners. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
(AsiaGameHub) - The British Horseracing Authority (BHA) has announced the appointment of Helen Bryce as its new General Counsel and Company Secretary, effective from 1 August 2026. This appointment is part of a significant restructuring of the governing body's leadership during a crucial time for UK racing.
Bryce will oversee all legal, compliance, risk management, and corporate governance operations, providing counsel to both the Executive and the Board on legal and statutory duties.
Her promotion signifies an internal progression, as she joined the BHA in 2017 and currently holds the position of Head of Legal and Governance.
Before her tenure at the BHA, Bryce spent ten years at Bird & Bird, where she served as a senior associate in their technology, media, and sport division, developing expertise in intricate regulatory and commercial matters.
She succeeds Catherine Beloff, who is leaving the organisation after more than a decade. During her time, Beloff managed two major governance reviews and established an independent judicial panel, contributing to the modernisation of the BHA’s regulatory framework.
Bryce expressed that it is a "huge privilege" to join the BHA at a pivotal moment for UK racing. She stated, "The BHA has a critical role to play in safeguarding the integrity and future of British racing. Maintaining the highest standards of corporate governance, legal compliance and transparency is fundamental to that mission.
“I look forward to working closely with colleagues and stakeholders across the industry to ensure that our policies and procedures not only meet regulatory expectations but also reinforce trust and accountability across the sport.”
BHA heads to negotiation table
Her appointment occurs amidst broader executive changes within the BHA. In March, Brant Dunshea officially took on the permanent role of CEO, having previously led the organisation on an interim basis following Julie Harrington's resignation in 2025.
Concurrently, the BHA is continuing its search for a new Chair, following the unexpected departure of Lord Charles Allen in February. His six-year term concluded amidst reported disagreements with stakeholders and racing bodies regarding governance direction.
The selection of a new Chair is considered vital. The BHA is preparing to enter negotiations with the Department for Culture, Media and Sport (DCMS) and bookmakers, represented by the Betting & Gaming Council (BGC), concerning the future funding model for the horseracing levy.
The redesign of the levy was notably excluded from the scope of the UK Gambling Review, a decision that has escalated tensions with bookmakers, some of whom have indicated they might withdraw from racing if terms are unfavourable.
Against this backdrop, Bryce's appointment is viewed as a move to bolster the BHA's legal and governance capabilities in anticipation of complex regulatory discussions. Prominent figures, including Matt Hancock, Ben Wallace, and HR veteran Julia Tyson, have already been mentioned as potential candidates for the vacant Chair position.
Commenting on the appointment, Dunshea remarked, “Helen has made a valuable contribution to the BHA and to British racing over a sustained period, demonstrating not only astute legal judgement but also a deep understanding of the governance challenges facing modern sport.
“At a time when the BHA must engage in complex discussions on funding, regulation and long-term sustainability, her expertise will be central to ensuring that we meet our statutory responsibilities while maintaining the confidence of participants, stakeholders and the public.”
He further added, “Her leadership will be instrumental as we navigate a period of structural change for racing, ensuring that our regulatory framework remains robust, transparent and fit for purpose.”
This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content.
AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
(AsiaGameHub) - Brazil’s tax authority, the Receita Federal (RF), projects a substantial increase in tax revenue from licensed online gambling by 2026.
This projection comes after a reported 235% surge in taxes collected in Q1 2026 from the 87 active licenses within the Brazil Bets market, according to SBC Noticias Brazil.
The federal government collected R$2.5bn (£350m) in taxes related to betting between January and February, a significant rise from the R$756m (£108.4m) gathered in the corresponding period of 2025.
January alone contributed R$1.49bn, with February yielding R$1.04bn. Analysts have suggested a possible seasonal dip in February, potentially linked to the Carnival festivities.
This sharp increase is attributed to the ongoing maturation of Brazil's regulated betting framework, which is now in its second year of full operation under Law No. 14,790/2023.
Market growth has been a primary factor, with the number of fully licensed operators growing from 49 at the start of 2025 to 87 by February 2026, leading to improved channelization and tax collection.
New fiscal measures were approved by Congress at the end of 2025 through Law No. 224/2025, introducing a gradual increase in the Gross Gaming Revenue (GGR) tax. The rate is set to rise from 12% to 13% in 2026, with a goal of reaching 15% by 2028.
According to RF Secretary Robinson Barreirinhas, the initial phase of this incremental adjustment is anticipated to generate an additional R$260m in tax revenue solely in 2026, bolstering the government's confidence in betting as a reliable source of fiscal income.
Based on current trends, the RF estimates that tax income from betting could range between R$11bn and R$13bn by the close of 2026, provided that sustained player demand supports the incremental tax increases.
This represents a steady year-on-year growth from the R$9.95bn collected in 2025, rather than an exponential leap.
Fuel to political fires
For policymakers, this trend highlights a broader objective: to strike a balance between revenue generation and regulatory oversight as Brazil continues to refine its gambling framework amidst political discussions regarding the social implications of gambling.
The Brazil Bets market is also undergoing several governance changes as it enters the spring season.
In March, the PT government appointed Dario Durigan as the new Secretary of the Ministry of Finance and the Economy, following Fernando Haddad's acceptance of the PT Party's nomination to run for governor of the State of São Paulo.
Concurrently, Daniele Cardoso has been confirmed as the new Secretary of the Secretariat of Prizes and Bets (SPA), the federal body responsible for regulating Brazil’s betting market, concluding months of industry speculation.
Collectively, the fiscal growth and the institutional changes signify a market transitioning rapidly from its launch phase to policy consolidation, as Brazil Bets continues to develop under increased political and regulatory scrutiny.
This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content.
AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
TOKYO and NEW YORK, NY., Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The filing will follow a standard review timeline.Taletrectinib (marketed as IBTROZI® in the U.S. and Japan) is a highly selective, next-generation oral treatment for patients living with advanced ROS1+ NSCLC.1 In January 2026, Eisai and Nuvation Bio announced they had entered into an exclusive licensing and collaboration agreement in Europe and additional countries* outside the U.S., China and Japan to extend the global reach of taletrectinib. Following this filing to the EMA, additional filings are planned for the U.K., Canada and other regions included in Eisai’s licensed territories.Across Europe, nearly 400,000 people are diagnosed with lung cancer each year with NSCLC accounting for 80% of cases.2,3 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5“The validation of the MAA is a significant moment for patients in Europe with ROS1+ NSCLC,” said Terushige Iike, Chief Business Officer of Eisai Co., Ltd. “With its efficacy and safety profile, we believe taletrectinib has the potential to become a standard of care therapy for the thousands of patients living with this aggressive disease in Europe. We look forward to working closely with the EMA during the review process with the goal of making this treatment available to appropriate patients who urgently need targeted options.”The application is based on data from the two pivotal Phase 2 clinical studies, TRUST-I and TRUST-II, evaluating taletrectinib in patients globally.6,7 Results from a pooled analysis of the TRUST clinical program were published in the Journal of Clinical Oncology in April 20258, and Nuvation Bio anticipates near-term disclosure of updated data reflecting even longer patient follow-up, further building on the depth and durability of responses observed to date. Additionally, given the comprehensive nature of the taletrectinib clinical dataset and based on favorable feedback received at a pre-submission meeting with the CHMP Rapporteur and Co-Rapporteur, the accepted MAA will be considered to support full approval.“Having seen the meaningful impact taletrectinib has already made for patients with ROS1+ NSCLC in the U.S., China and Japan, we are thrilled to partner with Eisai and have an accepted MAA for review in Europe,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “This accepted filing represents an important milestone in our global development strategy and brings us one step closer to delivering this highly selective, next-generation oral therapy to more patients who need it in Europe and around the world.”In June 2025, the U.S. Food and Drug Administration (FDA) granted full approval to taletrectinib for the treatment of locally advanced or metastatic ROS1+ NSCLC across lines of therapy, following a Priority Review and double Breakthrough Therapy designations. Taletrectinib is also approved for patients with advanced ROS1+ NSCLC in Japan, where it is marketed by Nippon Kayaku, and in China, where it is marketed by Innovent Biologics under the brand name DOVBLERON®.* Eisai’s licensed territories: Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and IndiaAbout ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer.9 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5 About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain.10 The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.10,11About TaletrectinibTaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Learn more about taletrectinib in the U.S. at IBTROZI.com. 1About the TRUST Clinical ProgramThe TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of taletrectinib. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating taletrectinib for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating taletrectinib for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating taletrectinib versus crizotinib in 138 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs.6,7About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.About Nuvation BioNuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).U.S. IndicationIBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ nonsmall cell lung cancer (NSCLC).IMPORTANT SAFETY INFORMATION FOR IBTROZI® (taletrectinib)1WARNINGS AND PRECAUTIONSHepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.ADVERSE REACTIONSAmong patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%).DRUG INTERACTIONSStrong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use.Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI. OTHER CONSIDERATIONSPregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity.Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose.Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible.Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established.Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation. Please see accompanying full U.S. Prescribing Information.(1) Nuvation Bio Inc. IBTROZI (taletrectinib) US prescribing information. Available at: https://ibtrozipi.com/IBTROZI_taletrectinib-prescribing-information.pdf. Last accessed: March 2026(2) Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. Available here. Last accessed: March 2026(3) European Lung Foundation. Lung cancer. Available here. Last accessed: March 2026(4) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(5) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131. doi:10.1056/NEJMoa2302299. (6) ClinicalTrials.gov. A Study of AB-106 in Advanced NSCLC With ROS1 Fusion (NCT04395677). Available at: https://clinicaltrials.gov/study/NCT04395677 . Last accessed: March 2026(7) ClinicalTrials.gov. A single-arm Phase 2 study of taletrectinib in advanced ROS1-positive NSCLC (NCT04919811). Available at: https://clinicaltrials.gov/study/NCT04919811 . Last accessed: March 2026(8) Pérol M, A., et al. Taletrectinib in ROS1-positive non-small cell lung cancer: TRUST. Journal of Clinical Oncology, 43(16), 1920–1929. https://doi.org/10.1200/JCO-25-00275(9) Global Data. Diagnosed incident cases of non-small cell lung cancer across 8MM to reach 1.46 million in 2032, forecasts GlobalData. Available here. Last accessed: March 2026(10) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(11) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Nuvation Bio Inc.Kaitlyn Nealymedia@nuvationbio.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Nuvation Bio Inc.JR DeVitair@nuvationbio.comForward-Looking Statements of Nuvation Bio Inc.Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding taletrectinib’s therapeutic potential and the urgent need for new therapeutic options for patients with advanced ROS1+ NSCLC in Europe, our expectations that the MAA filing for taletrectinib will follow a standard review with a decision in 1H 2027 and be considered for full approval, plans for additional filings for the U.K., Canada and other regions included in Eisai’s licensed territories, and expectations for near-term disclosure of updated data. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and commercialization, and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; physician and patient behavior; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-K filed with the SEC on March 2, 2026 under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
The Frst New Leo Liner "L00 Series"TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has completed delivery of the first trainsets L00 Series ("Leo-kei") trains (4 cars per trainset, total 12 cars) ordered by Seibu Railway Co., Ltd. for its Yamaguchi Line, an automated guideway transit (AGT) system. Commercial operation of the first train began on March 27th. That same day, Seibu Railway held a commemorative ceremony for the start of commercial operation, attended by Tokorozawa City Mayor Masatoshi Onozuka and Higashimurayama City Mayor Takashi Watanabe.The new L00 Series are being manufactured at MHI's Mihara Machinery Works in Hiroshima Prefecture, and are scheduled to be delivered sequentially by FY2027. The seating arrangement has been changed from the bench seats used in the existing 8500 Series vehicles to longitudinal seats to increase transport capacity to BELLUNA DOME baseball stadium and Seibuen Amusement Park. To meet diverse passenger needs, wheelchair spaces, children's seats, and in-car information displays have been installed to enhance convenience.In addition, the new trains incorporate many unique specifications designed by MHI especially for AGT system vehicles, including aluminum bodyshells, the MHI bogie,(1), a ceiling duct air conditioning system,(2) and A-MVCS (Advanced Mitsubishi Vehicle Control System). The A-MVCS in particular, in addition to the vehicle control function, has monitoring and commissioning functions for each piece of on-board equipment, allowing it to flexibly meet the needs of railway operators.Further, a large glass window has been installed in the partition wall between the driver's cab and the children's seat, allowing children to enjoy the view from the front window and driver's seat, enhancing the sense of excitement for passengers.This AGT system utilizes rubber tires for a smooth ride and low noise. In addition, as a type of clean mobility with low CO2 emissions, the system has a reduced environmental impact, supporting the realization of a decarbonized and energy-efficient world. The adoption of vehicles that combine excellent design and environmental performance also enhances the impression of the surrounding facilities.Going forward, MHI Group will continue to strive for technological innovation, and through services that safely and comfortably transport people and goods, contribute to the development of public transport that supports the lives of people around the world.(1) A bogie developed by MHI for AGT systems. It is compatible with general rubber tire operation for AGTs.(2) A system that directs air through ducts behind the ceiling to provide air conditioning.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
RESULTS HIGHLIGHTS:- The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of approximately 11.1% as compared with the same period last year.- The Gross Profit Margin for the year ended 31 December 2025 was approximately 55.8%; the gross profit was approximately HK$2,085.0 million, representing an increase of approximately 15.9% as compared with the same period last year.- The Group’s EBITDA for the year ended 31 December 2025 was approximately HK$938.1 million, representing an increase of approximately 32.4% as compared with the same period last year.- The Group’s net profit for the year ended 31 December 2025 was approximately HK$601.2 million, representing an increase of approximately 47.7% as compared with the same period last year.- Basic earnings per share for the year ended 31 December 2025 amounted to approximately HK63.7 cents, representing an increase of approximately 47.5% as compared with the same period last year.- The Board recommended the payment of a final dividend of HK15.0 cents per ordinary share for the year ended 31 December 2025.- For the year ended 31 December 2025, the Group recorded approximately 1,039,000 cases digital solution cases produced from the Group’s production facilities in Mainland China, Thailand and Vietnam, reflecting an increase of 32.7% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - 26 March 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, announces its annual results for the year ended 31 December 2025 (“the year”).During the year ended 31 December 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. The Group’s underlying fundamentals remain solid, and we are well positioned to capitalize on emerging opportunities going forward.European BusinessesDuring the year ended 31 December 2025, the European market recorded a revenue of approximately HK$1,887.0 million, representing an increase of approximately HK$268.0 million as compared with the year ended 31 December 2024. This geographic market accounted for 50.5% of the Group’s total revenue. The increase of revenue from the European market was mainly attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the frontrunner to provide comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed and will continue to equip ourselves to provide the state-of-the-art digital solutions offerings to the dental community in the market.North American BusinessesDuring the year ended 31 December 2025, the North American market recorded a revenue of approximately HK$696.4 million, representing a decrease of approximately HK$55.7 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 18.6% of the Group’s total revenue.A significant portion of our business in the North America region comprises higher-end products manufactured domestically by MicroDental Laboratories, Inc. and its subsidiaries (“MicroDental Group”). While demand for discretionary cosmetic treatments remained soft throughout 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers.Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties — an advantage that sets us apart from competitors. Although digitalization of imported product lines drove growth in mass market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a slow growth in sales for our import-focused business unit.Greater China BusinessesFor the year ended 31 December 2025, the Greater China market recorded a revenue of approximately HK$615.4 million, representing a decrease of approximately HK$46.8 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 16.5% of the Group’s total revenue.The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition and the situation started to stabilize in the second half of 2025. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesFor the year ended 31 December 2025, the Australian market recorded a revenue of approximately HK$289.1 million, representing an increase of approximately HK$24.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 7.7% of the Group’s total revenue. The increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 2.4% compared with the year ended 31 December 2024.Through our various brands, which offer onshore-and offshore-made products, at multiple price points ranging from economy and standard to premium/boutique, the Group is able to effectively penetrate the entire Australian market. We have invested in local production capacity to provide faster service to our customers, and to provide choices around where the products are made. The Group is one of the largest players in the Australian market and is a preferred supplier to the major corporate dental groups in the market.Other MarketsOther markets primarily include Thailand, Indian Ocean countries, Malaysia, Taiwan and Singapore. For the year ended 31 December 2025, these markets recorded a revenue of approximately HK$248.9 million, representing an increase of approximately HK$182.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 6.7% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalize on opportunities across regions.The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our record 2025 performance, the Group is well placed to sustain momentum and further strengthen its market leadership.Digitalization remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–40% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivered superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years.Following the successful integration of Hexa Ceram (Thailand’s largest dental laboratory, acquired in January 2025) and Digital Sleep Design (Proprietary nylon oral appliance to treat obstructive sleep apnea), our Southeast Asian presence and specialized capabilities have been significantly strengthened. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides enhanced flexibility to address potential trade and geopolitical risks while supporting faster regional delivery.Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HIGHLIGHTS:- Total gross billings amounted to approximately RMB3,955.0 million, representing an increase of approximately 12.8% from approximately RMB3,505.9 million for the corresponding period.- Total revenue was approximately RMB3,430.1 million, representing an increase of approximately 48.7% from approximately RMB2,306.0 million for the corresponding period.- The profit attributable to Shareholders of the Group was approximately RMB921.8 million, representing an increase of approximately 238.5% from approximately RMB272.4 million for the corresponding period.- Non-HKFRS adjusted profit for the year (excluding the share-based compensation expenses) was approximately RMB1,022.5 million, representing an increase of approximately 191.8% from approximately RMB350.5 million for the corresponding period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - JF SmartInvest Holdings Ltd (the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, leveraging its “technology + investment research” dual-drive strategy, the Group achieved outstanding performance. Supported by robust cash flow and profitability, the Board has proposed a final dividend of HK$0.36 per share, bringing the total dividend for the full year to approximately HK$407.4 million when combined with the interim dividend already paid, reflecting its commitment to delivering returns to shareholders.Strong Financial Performance with Substantial Profitability ImprovementDuring the Reporting Period, the Group continued to advance product innovation, AI applications, and investment research capabilities, driving solid growth across its business. Total revenue for the year reached RMB3,430.1 million, representing a YOY increase of 48.7%. Gross profit amounted to RMB2,821.0 million, up 48.9% YOY, while the gross profit margin remained at a high level of 82.2%, indicating the favourable economies of scale and earnings quality of the Group’s business model.In terms of profitability, profit attributable to equity shareholders surged by 238.5% YOY to RMB921.8 million. Excluding share-based compensation expenses, non-HKFRS adjusted profit for the year reached RMB1,022.5 million, representing a YOY increase of 191.8%, fully demonstrating the effective strategy execution and market adaptability of the Group.The Group places great emphasis on shareholder returns. The Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash). Together with the interim dividend of approximately HK$238.9 million already distributed, the total dividend for 2025 will amount to approximately HK$407.4 million. The steady dividend policy fully reflects the Group’s ample cash reserves and its firm confidence in future development prospects.Continued Optimisation of Product Matrix and Enhancement of Diversified Service SystemDuring the Reporting Period, the Group continued to build a diversified product matrix, enriching its product portfolio in response to different customer needs. VIP products 'Stock Navigator, Super Investor' were steadily optimized, with the addition of several quantitative products and AI-powered products. We also launched a 24/7 AI intelligent customer service system, which significantly improved service efficiency. The live streaming system was upgraded, with sessions increasing by 36% YOY and average daily unique viewers exceeding 100,000.Relying on an integrated “AI + content + service + tools” solution, the Enjoy-Stock Pad recorded net sales volume exceeding 75,000 units during the Reporting Period. The Jiuyao Stocks launched over 80 lightweight products, converting professional investment research capabilities into standardised products. The SmartInvest APP completed its strategic transformation from a tool to a platform, with monthly active users increasing by more than 40% YOY and the 30-day retention rate remaining above 50%.The Group further enhanced its product matrix with two new products, Decision Master and Star-tier Services, filling the gap in the mid-tier product system and enabling a seamless trading service experience. Decision Master focuses on three AI+ investment research modules - themes, value investing and quantification - comprehensively enhances investment decision-making capabilities of individual investors. Star-tier Services collaborates with multiple securities brokerages and partners to create a fully integrated closed-loop ecosystem of“tools-services-trading”, serving over 50,000 users during the Reporting Period.Guided by Technological Innovation, Striving Towards “Investment Advisory Intelligent Agent 2.0”The Group regards innovation and technological R&D as its core driving force, accelerating its transformation towards “digital intelligence”, and advancing towards the era of “investment advisory intelligent agent 2.0”. During the Reporting Period, R&D expenses amounted to approximately RMB356 million, with R&D personnel reaching 624, a YOY increase of approximately 42.8%. The Group held 158 software copyrights and patents in AI, big data and product features, with 22 new items added on a year-on-year basis.The self-developed FinSphere Agent Large Model Assistant V3.0 passed the Large Model Assistant Functionality Completeness Test conducted by the China Academy of Information and Communications Technology, becoming the first large-model application in the securities industry. During the Reporting Period, it served approximately 664,000 customers with cumulative services of 22.58 million. The digital intelligent investment robo-advisor “Jiu Ge” served approximately 600,000 customers with cumulative services exceeding 19 million. The Group also launched stock diagnosis intelligent agent 4.0, AI Xiaoce Q&A assistant, and established an intelligent compliance and risk control platform covering the entire business workflow, indicating that the group's AI capabilities have gradually been implemented in core scenarios.To strengthen its technological foundation, the Group established a technology subsidiary, Jiufang Zhiqing, and set its foothold in “Shanghai Foundation Model Innovation Center”, China’s first large model innovation ecosystem community. The subsidiary serves as the Group’s core AI vehicle for operating a native service technology system, promoting the deep application of AI in scenarios such as investment research, investor education, and risk control.Deep-Rooted Investment Research as the Cornerstone, Adhering to Buyer-Side Advisory and Deepening the “1+N” Investment Research SystemThe Group continues to deepen its “1 research institute and N business lines” investment research system, with the JF Financial Research Institute as investment research hub. The Institute has established a pyramidal-structured professional talent echelon led by Chief Economist Dr. Xiao Lisheng, comprising 4 experts, 8 super-IPs and 128 professionals. As of the end of the Reporting Period, the Group had 576 employees holding securities investment advisory qualifications and 2,628 employees holding securities practitioners, maintains a leading team scale and structure in the industry.During the Reporting Period, The Institute conducted more than 300 research activities, covering more than 2,000 listed companies. The Institute authored approximately 1,200 in-depth research reports and 45 sets of thematic courses with a total duration of 2,000 minutes, continuously enhancing the professional capabilities of buyer-side consultants.Multi-Dimensional, Full-Funnel Traffic Operation to Unlock New Growth DimensionsDriven by AI technology, the Group positions refined MCN-based traffic operations as a central hub connecting users with its business, building an integrated, synergistic omni-channel traffic ecosystem comprising “public-domain MCN (multi-platform) + private-domain + proprietary APP”. On the technological front, the Group applied AIGC to restructure content production, shifting from manual creation to “human-machine collaboration” model, and established a data flywheel integrating “advertising data, model training and operational automation”. During the Reporting Period, the Group consolidated its leading position on online short-video and live streaming platforms’ operations, established a multi-platform coordinated traffic matrix, and developed a multi-tiered, high-quality content ecosystem. It also pioneered e-commerce models for the Enjoy-Stock Pad and AppStore models for the APP, driving deep integration between traffic operations and product features.Future OutlookMr. Chen Wenbin, chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, said: “In 2025, we remained committed to the dual-drive strategy of ‘technology + investment research’. Not only did we achieve leapfrog growth in performance, but we also successfully led the industry into the era of ‘Investment Advisor Agent 2.0’. Leveraging artificial intelligence and big data technologies, we developed AI products such as the JF Robo-Advisor, FinSphere Agent and FinSphere Report, achieving industry-leading innovations and scenario-based applications, helping users accomplish the critical transition from ‘cognitive improvement’ to ‘decision optimisation’. At the same time, we transformed our professional investment research capabilities into easily accessible lightweight services, realising a strategic shift ‘from tool to platform’. We uphold the principles of rational investing, value investing and long-term investing, assisting clients in developing sound investment philosophies.“In the future, the Group will focus on four key strategic dimensions. First, deepening AI-driven empowerment across all scenarios, accelerating the iteration of AI agents and their commercialisation on the consumer side, and driving the Group’s digital and intelligent transformation. Second, leveraging Forthright Securities and Forthright Capital’s licenses, advancing the globalisation strategy by exporting the Jiufang’s core models, accelerating overseas business expansion. Meanwhile, promoting license upgrading and strategic investment layout to further improve the construction of digital asset infrastructure. Third, strengthening product-driven business diversification and synergies, deepening cooperation with licensed financial institutions such as securities brokerages, and building a service closed loop covering pre-investment, in-investment and post-investment. Fourth, continuing to optimize the customer operation system, unlocking the value of traffic through full-funnel traffic initiatives, and achieving long-term customer retention. We are dedicated to making investing simpler and more professional while enhancing investors’ sense of fulfillment in investment and wealth management.”About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, the AI Stock Machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
